Claims

1. A compound according to Formula I



Meta or para (Formula **I**)

or a pharmaceutically acceptable salt thereof wherein:

- A_{11} – A_{14} are N or CR_{11}, CR_{12}, CR_{13}, CR_{14}, respectively, with the proviso that no more than two of the four positions A can be simultaneously N;
- R_1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino, with all carbon atoms of alkyl groups optionally substituted with one or more F and all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl;
- R_2 and R_3 are independently H, F, methyl, ethyl, hydroxy, methoxy or R_2 and R_3 together is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F;
- R_4 is H or C(1-6)alkyl;
- R_5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl, all groups optionally substituted with one or more F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano;
- the sulfonyl group with R_1 is represented by one of R_7, R_8 or R_9;

- the remaining R_6-R_{14} are independently H, halogen, amino, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all of the alkyl groups optionally being substituted with one or more F;
- R_{15} is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano; and,
- R_{16} is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano.

2. The compound according to claim 1 wherein:

- A_{11} – A_{14} are N or CR_{11}, CR_{12}, CR_{13}, CR_{14}, respectively, with the proviso that no more than two of the four positions A can be simultaneously N;
- R_1 is C(2-6)alkyl, C(3-6)cycloalkylC(1-3)alkyl or (di)C(3-6)cycloalkylamino, with all carbon atoms of alkyl groups optionally substituted with one or more F and all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl;
- R_2 and R_3 are independently H, methyl, or R_2 and R_3 together is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F;
- R_4 is H;
- R_5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)arylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl, all groups optionally substituted with one or more F, C(1-2)alkyl, C(1-2)alkoxy or cyano;
- the sulfonyl group with R_1 is represented by R_8;
- the remaining R_6-R_{14} are independently H, halogen, C(1-3)alkoxy or C(1-6)alkyl, all of the alkyl groups optionally being substituted with one or more F;
- R_{15} is C(1-6)alkyl optionally substituted with one or more F, or C(1-9)heteroaryl substituted with one C(1-2)alkyl; and,

- R_{16} is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl, all groups optionally substituted with one or more F.

3. The compound according to claim 1 or claim 2, wherein:
   - A_{11} – A_{14} is CR_{11}, CR_{12}, CR_{13}, CR_{14};
   - R_1 is C(2-6)alkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino; ←
   - R_2 and R_3 are independently H or methyl;
   - R_4 is H;
   - R_5 is H, C(1-6)alkyl or C(6-10)arylC(1-3)alkyl;
   - the sulfonyl group with R_1 is represented by R_8;
   - the remaining R_6-R_{14} are independently H or C(1-6)alkyl;
   - R_{15} is C(1)alkyl optionally substituted with one or more F, or C(3)heteroaryl substituted with one methyl; and,
   - R_{16} is C(1-6)alkyl, C(3-6)cycloalkyl, C(6-10)aryl or C(6-10)arylC(1-3)alkyl, all groups optionally substituted with one or more F.

4. The compound according to claim 1, wherein:
   - A_{11} or A_{14} is N, the remaining position A being CR_{11} or CR_{14};
   - A_{12} and A_{13} are respectively CR_{12} and CR_{13};
   - R_1 is C(3-6)cycloalkylC(1-3)alkyl;
   - R_2 and R_3 are independently H;
   - R_4 is H;
   - R_5 is H;
   - the sulfonyl group with R_1 is represented by R_8;
   - the remaining R_6-R_{14} are independently H or methyl; and,
   - R_{15} and R_{16} are C(1)alkyl, with all carbon atoms of alkyl groups optionally substituted with one or more F.

5. The compound as defined in claim 1 which is selected from the group of :
   . N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-hydroxy-1-(trifluoromethyl)propyl]benzamide;
   . (-)-N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-hydroxy-1-(trifluoromethyl)propyl]benzamide;

- (+)-N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-hydroxy-1-(trifluoromethyl)propyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-(1-hydroxy-1-methyl-ethyl)benzamide
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-(difluoromethyl)-2,2,2-trifluoro-1-hydroxy-ethyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-hydroxy-1-(trifluoromethyl)butyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-hydroxy-1-(trifluoromethyl)pentyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-hydroxy-3-methyl-1-(trifluoromethyl)butyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-hydroxy-3,3-dimethyl-1-(trifluoromethyl)butyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-hydroxy-2-methyl-1-(trifluoromethyl)propyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxy-ethyl)benzamide;
- 4-(1-cyclopentyl-2,2,2-trifluoro-1-hydroxy-ethyl)-N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-(2,2,2-trifluoro-1-hydroxy-1-phenyl-ethyl)benzamide;
- 4-(1-benzyl-2,2,2-trifluoro-1-hydroxy-ethyl)-N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-3-methyl-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]pyridine-2-carboxamide;
- N-[(4-ethylsulfonylphenyl)methyl]-4-[1-hydroxy-1-(trifluoromethyl)propyl]benzamide

- N-[(4-ethylsulfonylphenyl)methyl]-4-[1-hydroxy-3,3-dimethyl-1-(trifluoromethyl)butyl]benzamide;
- N-[(4-ethylsulfonylphenyl)methyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylsulfamoyl)phenyl]methyl]-4-[1-hydroxy-1-(trifluoromethyl)pentyl]benzamide;
- N-[[4-(cyclopropylsulfamoyl)phenyl]methyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-ethoxy-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[2,2,2-trifluoro-1-propoxy-1-(trifluoromethyl)ethyl]benzamide;
- 4-[1-butoxy-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]-N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[2,2,2-trifluoro-1-isopropoxy-1-(trifluoromethyl)ethyl]benzamide;
- 4-[1-benzyloxy-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]-N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)-2-methyl-phenyl]methyl]-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)-2-methyl-phenyl]methyl]-4-[1-ethoxy-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylsulfamoyl)phenyl]methyl]-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylsulfamoyl)phenyl]methyl]-4-[1-ethoxy-2,2,2-trifluoro-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylsulfamoyl)phenyl]methyl]-4-[2,2,2-trifluoro-1-propoxy-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-methoxy-3,3-dimethyl-1-(trifluoromethyl)butyl]benzamide;
- N-[(1R)-1-[4-(cyclopropylmethylsulfonyl)phenyl]ethyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide;

- N-[(1S)-1-[4-(cyclopropylmethylsulfonyl)phenyl]ethyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide;
- N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]-4-[1-hydroxy-2-methyl-1-(5-methylisoxazol-3-yl) propyl]benzamide;
- 4-[cyclopropyl-hydroxy-(5-methylisoxazol-3-yl)methyl]-N-[[4-(cyclopropylmethylsulfonyl)phenyl]methyl]benzamide; and,
- N-[(4-(cyclopropylmethylsulfonyl)phenyl)methyl]-4-[1-hydroxy-2,2-dimethyl-1-(5-methylisoxazol-3-yl)propyl]benzamide.

6. Medicament, characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof.

7. Compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in therapy.

8. Pharmaceutical composition which comprises a compound of Formula I according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

9. Pharmaceutical composition according to claim 8 which further comprises at least one additional therapeutically active agent.

10. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn’s disease or multiple sclerosis.

11. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of osteoarthritis or asthma.

12. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of mucosal leishmaniasis.

13. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of Kawaski disease or Hashimoto's thyroiditis.

14. The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in the treatment of RORγ-mediated cancer, RORγ-mediated autoimmune diseases or RORγ-mediated respiratory diseases.